Regeneron Pharmaceuticals Inc

2026. g. 2. jūl. 23:26 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, despite a lower-than-expected jobs report easing rate hike fears and boosting sentiment for some risk assets.

2026. g. 1. jūl. 19:16 UTC

Regeneron Pharmaceuticals is trading higher, reflecting positive biotechnology sector performance. The stock remains above its 20-day moving average and near a one-month peak.

2026. g. 30. jūn. 23:16 UTC

Regeneron Pharmaceuticals shares remain roughly flat in after-market trading, following three consecutive sessions of declines and no specific news identified.

2026. g. 29. jūn. 23:06 UTC

Regeneron Pharmaceuticals will join the FDA's PreCheck Pilot Program to enhance domestic drug manufacturing. Shares are trading lower in after-market hours.

2026. g. 26. jūn. 23:36 UTC

Regeneron Pharmaceuticals Inc shares are trading higher in after-market hours, moving within a notable range above their 20-day moving average.

2026. g. 25. jūn. 23:16 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, retracing from an early peak following five consecutive daily gains. No specific news was identified.

2026. g. 24. jūn. 23:01 UTC

Regeneron Pharmaceuticals Inc shares are lower after-market hours, continuing a decline since Wednesday's close amid positive sentiment in the financial sector.

2026. g. 23. jūn. 23:06 UTC

Regeneron Pharmaceuticals Inc shares are trading lower in after-market hours. Broader market trends may be influencing the stock's movement amid European market declines.

2026. g. 22. jūn. 19:56 UTC

Regeneron Pharmaceuticals' cemdisiran submissions accepted by the FDA and European Medicines Agency. Shares are gaining amid positive regulatory developments.

2026. g. 18. jūn. 23:51 UTC

Regeneron Pharmaceuticals traded roughly flat in after-market hours, reflecting a slight decline since Thursday's close and remaining near the lower end of its one-month range.

2026. g. 17. jūn. 19:53 UTC

Regeneron Pharmaceuticals is declining in Wednesday's session, despite positive U.S. retail sales data. Shares remain below their 20-day moving average.

2026. g. 16. jūn. 19:16 UTC

Regeneron Pharmaceuticals Inc shares are lower today, with no specific news identified. Broader market sentiment may be affected by recent economic data.

2026. g. 15. jūn. 13:36 UTC

Regeneron Pharmaceuticals Inc shares are lower in pre-market hours. The stock is near the lower end of its one-month range, indicating routine price action.

2026. g. 13. jūn. 00:01 UTC

Regeneron Pharmaceuticals shares are modestly higher in after-market trading, though no specific news was identified to explain the movement.

2026. g. 12. jūn. 19:16 UTC

Shares of Regeneron Pharmaceuticals are modestly higher today, gaining traction after a flat start. The stock remains below its 20-day moving average.

2026. g. 11. jūn. 23:02 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, rebounding from earlier fluctuations despite no specific news to explain the movement.

2026. g. 10. jūn. 23:11 UTC

Regeneron Pharmaceuticals is trading higher in after-market hours, supported by a rise in the Biotechnology sub-sector. The stock remains near its one-month low.

2026. g. 9. jūn. 19:56 UTC

Regeneron Pharmaceuticals shares are higher following WHO's endorsement of its antibody therapy maftivimab for clinical trials against Bundibugyo ebolavirus.

2026. g. 8. jūn. 23:51 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, recovering from earlier lows amid broader market dynamics influenced by recent U.S. jobs data.

2026. g. 5. jūn. 20:07 UTC

Regeneron Pharmaceuticals shares are higher as Teva launches AHZANTIVE, a biosimilar to Eylea, enhancing its ophthalmology portfolio and impacting Regeneron's competitive position.

2026. g. 4. jūn. 19:56 UTC

Regeneron Pharmaceuticals is gaining momentum ahead of presentations at major medical conferences in June, showcasing new clinical data on key therapies.

2026. g. 3. jūn. 23:01 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, following a session peak. No specific news was identified to explain the movement.

2026. g. 2. jūn. 23:21 UTC

Regeneron Pharmaceuticals is trading higher in after-market hours, driven by gains in the Biotechnology sub-sector, marking a notable change from recent performance.

2026. g. 1. jūn. 20:03 UTC

Regeneron Pharmaceuticals is under pressure following an investigation announcement by Bronstein, Gewirtz & Grossman, LLC, amid concerns over trial results. Shares are trading lower.

2026. g. 29. maijs 20:05 UTC

Regeneron Pharmaceuticals shares declined following the WHO's recommendation to evaluate maftivimab amid an Ebola outbreak in the Democratic Republic of the Congo and Uganda.

2026. g. 28. maijs 23:02 UTC

Regeneron Pharmaceuticals shares rise after WHO recommends maftivimab for use against the Bundibugyo ebolavirus outbreak in Africa.

2026. g. 27. maijs 23:21 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, recovering from recent declines but remain below the 20-day moving average. No specific news was identified.

2026. g. 26. maijs 23:06 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, continuing a recent trend of declines amid broader market weakness and no specific news identified.

2026. g. 22. maijs 19:37 UTC

Regeneron Pharmaceuticals shares are lower today amid investor caution following an investigation into potential claims related to prior trial results.